Developing targeted therapies for lung cancer.
Gandara
David R
DR
University of California, Davis Cancer Center, USA.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D002986:Clinical Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D003603:Cytotoxins / Q000627:therapeutic use; D004273:DNA, Neoplasm / Q000187:drug effects; D016503:Drug Delivery Systems; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000276:immunology; D051231:Farnesyltranstransferase / Q000037:antagonists & inhibitors; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000276:immunology; D012107:Research Design
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D003603:Cytotoxins; D004273:DNA, Neoplasm; D004791:Enzyme Inhibitors; D009363:Neoplasm Proteins; D051231:Farnesyltranstransferase; D066246:ErbB Receptors